Zoetis Reports Q3 2026 Revenue Decline Amid Pet Care Pressures and Livestock Growth
Zoetis (ZTS) reported a 1% decline in organic operational revenue for the third quarter of 2026, driven primarily by a 5% drop in companion animal revenue. The company faced headwinds from reduced veterinary clinic visits and increased generic competition within its dermatology portfolio. To combat market share loss, management utilized targeted promotional discounts to defend key accounts. Despite weaknesses in pet care, the global livestock segment provided a significant buffer, with revenues rising 7% to $797 million due to demand for cattle treatments and poultry vaccines. Looking forward, Zoetis is focusing on lifecycle innovation—such as early approvals for Convenia RTU and Simparica Duo—to extend product franchises. Management remains cautious heading into 2027, citing lingering macro trends and pricing pressures.
Tickers: $ZTS
Topics: livestock revenue growth pet care market share quarterly earnings revenue decline